Abstract

Gastric cancer continues to be one of the most important gastrointestinal cancers. Despite improved surgery and resection rates of 30%-60% still most of the patients die of loco-regional recurrence or distant metastasis. The role of adjuvant and palliative treatment of gastric cancer has world-wide been assessed in uncontrolled and prospective studies. Many of those were insufficient with respect to the number of patients and inclusion of prognostic factors as stratification criteria. Furthermore, the radiation oncologist would have preferred if these studies had looked at loco-regional tumor control instead of response rates or overall survival. A comprehensive overview of the currently available data for radiation therapy in adjuvant and palliative treatment schedules of gastric cancer is given and the limits of these studies are critically discussed. Until now, there is no clear evidence of improved overall survival from the addition of radiation therapy. However, the data suggest radiation therapy might be an effective measure to reduce loco-regional recurrence rates and similarly increase the recurrence-free survival. For the next future, optimally designed phase III trials with sufficient numbers of patients should be initiated to assess the definite value of radiation therapy for gastric cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.